Entry

D09979                      Drug

Name

Tralokinumab (USAN/INN);
Tralokinumab (genetical recombination) (JAN);
Tralokinumab-ldrm;
Adbry (TN);
Adtralza (TN)

Product

ADBRY (LEO Pharma)

Formula

C6374H9822N1698O2014S44

Exact mass

143784.6063

Mol weight

143873.2167

Sequence

(Heavy chain)
QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYGLSWVRQA PGQGLEWMGW ISANNGDTNY
GQEFQGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARDS SSSWARWFFD LWGRGTLVTV
SSASTKGPSV FPLAPCSRST SESTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ
SSGLYSLSSV VTVPSSSLGT KTYTCNVDHK PSNTKVDKRV ESKYGPPCPS CPAPEFLGGP
SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS
TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM
TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ
EGNVFSCSVM HEALHNHYTQ KSLSLSLGK
(Light chain)
SYVLTQPPSV SVAPGKTARI TCGGNIIGSK LVHWYQQKPG QAPVLVIYDD GDRPSGIPER
FSGSNSGNTA TLTISRVEAG DEADYYCQVW DTGSDPVVFG GGTKLTVLGQ PKAAPSVTLF
PPSSEELQAN KATLVCLISD FYPGAVTVAW KADSSPVKAG VETTTPSKQS NNKYAASSYL
SLTPEQWKSH RSYSCQVTHE GSTVEKTVAP TECS
(Disulfide bridge: H22-H96, H149-H205, H263-H323, H369-H427, H228-H'228, H231-H'231, L22-L87, L136-L195, H136-L213)

Type

Peptide

Class

Immunological agent
DG02019 Interleukin inhibitor

Remark

ATC code:

D11AH07

Product:

D09979<US>

Efficacy

Antiasthmatic, Anti-inflammatory, Anti-IL-13 antibody

Disease

Atopic dermatitis [DS:H01358]

Comment

Monoclonal antibody
Treatment of asthma and inflammatory diseases

Target

IL13 [HSA:3596] [KO:K05435]

Pathway

hsa04060

Cytokine-cytokine receptor interaction

hsa04630

JAK-STAT signaling pathway

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
D DERMATOLOGICALS
  D11 OTHER DERMATOLOGICAL PREPARATIONS
   D11A OTHER DERMATOLOGICAL PREPARATIONS
    D11AH Agents for dermatitis, excluding corticosteroids
     D11AH07 Tralokinumab
      D09979  Tralokinumab (USAN/INN) <US>
Drug groups [BR:br08330]
Immunological agent
  DG02019  Interleukin inhibitor
   D09979  Tralokinumab
Drug classes [BR:br08332]
Immunological agent
  DG02019  Interleukin inhibitor
   D09979  Tralokinumab
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
  Cytokines
   Interleukins
    IL13
     D09979  Tralokinumab (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D09979
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D09979
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D09979

Other DBs

CAS:	1044515-88-9

PubChem:

135626700